About Rexcin Drugs Private Limited
Data last updated:
Rexcin Drugs Private Limited is a private limited company based in New Delhi, Delhi, India. It operates in the chemical products segment of the chemicals sector. It was incorporated on 16 December 2003 and has been in existence for over 23 years.
The company is registered with the Registrar of Companies (ROC), Delhi, under CIN U24239DL2003PTC123543. The company has 2 GST registrations on record, none of which is active.
The company has an authorised share capital of ₹1 Lakh and a paid-up capital of ₹1 Lakh. It is led by directors Satinder Pal Singh and Pradeep Saxena.
Its last annual general meeting (AGM) was held on 30 September 2025, and its latest financial statements are for the year ended 31 March 2025. The registered office is at Flat No. 17 – B First Floor Block A – 1A Janakpuri, New Delhi, Delhi, India – 110058.
As per the financials filed for FY 2025, the company reported a revenue of ₹53,360, a growth of 85% compared to the previous year. For the same year it recorded a net profit of ₹87.25 Lakh and EBITDA of ₹87.39 Lakh. Revenue has grown at a compounded annual rate (CAGR) of 27% over three years and 5% over five years.
The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website rexcinpharma.com.
Company details
Contact details
Rexcin Drugs Private Limited's registered office is in New Delhi, Delhi. Its website is rexcinpharma.com. Its e-mail address and telephone number are in the company report.
- Email
- Telephone
- Website
- Registered AddressFlat No. 17 – B First Floor Block A – 1A Janakpuri, New Delhi, Delhi, India – 110058
- IndustryChemicals, Chemical Products, Medicinal Chemical & Botanical Products, Pharmaceuticals
To see the full contact details of Rexcin Drugs Private Limited, buy the company report.
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
Financials of Rexcin Drugs Private Limited
FY 2025 filings availableRexcin Drugs Private Limited reported revenue of ₹53,360 (up 85% YoY) for FY 2025.
Compounded Annual Growth Rate (CAGR)
Revenue has grown at a compounded annual rate (CAGR) of 5% over five years, including 85% growth in the latest year. EBITDA rose 30% in the latest year. Three- and five-year figures are compounded annual growth rates (CAGR): the steady yearly rate that links the first and the last year. All are worked out from the filed statements.
Financial Statement Summary
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profit and Loss Statement | |||||
| Revenue from Operations | |||||
| Other Income | |||||
| Total Revenue | |||||
| Cost of Materials Consumed | |||||
| Employee Benefit Expense | |||||
| Finance Costs | |||||
| Depreciation and Amortisation | |||||
| Other Expenses | |||||
| Total Expenses | |||||
| EBITDA | ₹87.39 Lakh | ||||
| Profit Before Tax | |||||
| Tax Expense | |||||
| Net Profit (PAT) | ₹87.25 Lakh | ||||
| Balance Sheet | |||||
| Share Capital | |||||
| Reserves and Surplus | |||||
| Net Worth (Total Equity) | |||||
| Long-term Borrowings | |||||
| Short-term Borrowings | |||||
| Trade Payables | |||||
| Total Liabilities | |||||
| Fixed Assets | |||||
| Investments | |||||
| Inventories | |||||
| Trade Receivables | |||||
| Cash and Bank Balance | |||||
| Total Assets | |||||
Financial Ratios
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profitability | |||||
| EBITDA Margin | |||||
| Net Profit Margin | |||||
| Return on Equity (ROE) | |||||
| Return on Capital Employed (ROCE) | |||||
| Return on Assets (ROA) | |||||
| Liquidity and Debt | |||||
| Current Ratio | |||||
| Quick Ratio | |||||
| Debt-to-Equity Ratio | |||||
| Interest Coverage Ratio | |||||
| Efficiency and Growth | |||||
| Asset Turnover | |||||
| Receivable Days | |||||
| Payable Days | |||||
| Inventory Days | |||||
| Revenue Growth | |||||
| Net Profit Growth | |||||
To see the full financial statements and ratios of Rexcin Drugs Private Limited, buy the company report.
Board of directors of Rexcin Drugs Private Limited
Rexcin Drugs has 2 current directors and 10 former directors. Current directors are listed first, with their designation and appointment date.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Satinder Pal Singh | Director | 17 Mar 2011 | 15 Years 7 Months | Current |
| Pradeep Saxena | Director | 29 Mar 2018 | 8 Years 6 Months | Current |
Auditor
Rexcin Drugs Private Limited is audited by HARISH GAMBHIR & Co. for the financial year 2017.
| Auditor firm | Financial year | Firm registration number |
|---|---|---|
| HARISH GAMBHIR & Co. | FY 2017 | 085426 |
Shareholding
The shareholding of Rexcin Drugs Private Limited is on record for 2 financial years, the latest being FY 2017, split between promoters, domestic institutions, foreign institutions, public shareholders and others.
| Shareholder category | FY 2017 | FY 2016 |
|---|---|---|
| Promoters | ||
| Domestic institutional investors (DII) | ||
| Foreign institutional investors (FII) | ||
| Public | ||
| Others |
To see the full shareholding pattern of Rexcin Drugs Private Limited, buy the company report.
Legal cases
No court or tribunal cases involving Rexcin Drugs Private Limited are on our record; a case search with case numbers, parties and status is in the company report Buy the company report.
MSME payment delays
No delayed payments to MSME suppliers are on our record for Rexcin Drugs Private Limited; the supplier-wise MSME Form 1 check is in the company report Buy the company report.
Group structure & subsidiaries
Rexcin Drugs has 2 associated companies. This group structure data is as of FY 2017. The table lists each entity with its relationship and holding.
GST
Rexcin Drugs has 2 GST registrations on record, and all of them have been cancelled or are inactive. Only active GST numbers are listed on this page.
To see the full GST registrations and return filing status of Rexcin Drugs Private Limited, buy the company report.
Recent activity
Rexcin Drugs Private Limited has 12 board changes on record since 2008: 2 appointments and 10 cessations. The latest: Pradeep Saxena ceased to be Additional Director on 27 Sep 2018.
3 earlier events are in the company report.
Frequently asked questions
Rexcin Drugs is an active private limited company based in New Delhi, Delhi, India. The company works in chemical products, within the chemicals industry. It was incorporated on 16 December 2003 (23+ years old) and is registered under CIN U24239DL2003PTC123543.
Rexcin Drugs has 2 current directors:
- Satinder Pal Singh - Director
- Pradeep Saxena - Director
The latest financial statements of Rexcin Drugs on record with the MCA are for the year ended 31 March 2025. Its last annual general meeting was held on 30 September 2025. Year-wise statements from 2015 are in the company report.
No. Rexcin Drugs has 2 GST registrations on record and all of them are cancelled or inactive.
The CIN (Corporate Identification Number) of Rexcin Drugs is U24239DL2003PTC123543. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Rexcin Drugs was incorporated on 16 December 2003, making it 23+ years old. It is registered with the Registrar of Companies, Delhi.
Pradeep Saxena ceased to be Additional Director on 27 Sep 2018. Sanjay Kumar Khar ceased to be Additional Director on 09 Apr 2018. Pradeep Saxena was appointed as Director on 29 Mar 2018. Rexcin Drugs has 12 board changes on record in total.
Rexcin Drugs can be reached through the website rexcinpharma.com. Its registered office is in New Delhi, Delhi, India.
The registered office of Rexcin Drugs is at Flat No. 17 – B First Floor Block A – 1A Janakpuri, New Delhi, Delhi, India – 110058.
Rexcin Drugs operates in the chemicals industry, in the chemical products segment.